Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913950552> ?p ?o ?g. }
- W2913950552 endingPage "171" @default.
- W2913950552 startingPage "157" @default.
- W2913950552 abstract "Parkinson's disease (PD) is a progressive neurological motor control disorder. A key feature is the loss of midbrain dopaminergic neurons and the accumulation of aggregated alpha-synuclein (α-syn). No current treatment is on the market that slows or halts disease progression. Previous studies have shown that glucagon-like peptide-1 (GLP-1) receptor agonists have neuroprotective effects in animal models of PD. In addition, in a phase II clinical trial, the GLP-1 receptor agonist exendin-4 has shown good protective effects in PD patients. In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD. Both drugs are currently on the market as a treatment for Type II diabetes. Our results show that both semaglutide and liraglutide improved MPTP-induced motor impairments. In addition, both drugs rescued the decrease of tyrosine hydroxylase (TH) levels, reduced the accumulation of α-syn, alleviated the chronic inflammation response in the brain, reduced lipid peroxidation, and inhibited the mitochondrial mitophagy signaling pathway, and furthermore increased expression of the key growth factor GDNF that protects dopaminergic neurons in the substantia nigra (SN) and striatum. Moreover, the long- acting GLP-1 analogue semaglutide was more potent compared with once daily liraglutide in most parameters measured in this study. Our results demonstrate that semaglutide may be a promising treatment for PD. A clinical trial testing semaglutide in PD patients will start shortly." @default.
- W2913950552 created "2019-02-21" @default.
- W2913950552 creator A5026936543 @default.
- W2913950552 creator A5056919701 @default.
- W2913950552 creator A5067028141 @default.
- W2913950552 creator A5082707086 @default.
- W2913950552 date "2019-02-05" @default.
- W2913950552 modified "2023-10-13" @default.
- W2913950552 title "Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease" @default.
- W2913950552 cites W1539187429 @default.
- W2913950552 cites W169987683 @default.
- W2913950552 cites W1890054393 @default.
- W2913950552 cites W1965095016 @default.
- W2913950552 cites W1966591940 @default.
- W2913950552 cites W1967178211 @default.
- W2913950552 cites W1967442749 @default.
- W2913950552 cites W1969800514 @default.
- W2913950552 cites W1979591162 @default.
- W2913950552 cites W1992788802 @default.
- W2913950552 cites W1993250284 @default.
- W2913950552 cites W1996170441 @default.
- W2913950552 cites W1997906954 @default.
- W2913950552 cites W2000631088 @default.
- W2913950552 cites W2004416309 @default.
- W2913950552 cites W2006568691 @default.
- W2913950552 cites W2007649442 @default.
- W2913950552 cites W2019530565 @default.
- W2913950552 cites W2022847635 @default.
- W2913950552 cites W2028955297 @default.
- W2913950552 cites W2030270894 @default.
- W2913950552 cites W2038976751 @default.
- W2913950552 cites W2043381283 @default.
- W2913950552 cites W2054810445 @default.
- W2913950552 cites W2065372294 @default.
- W2913950552 cites W2068288454 @default.
- W2913950552 cites W2068495410 @default.
- W2913950552 cites W2069491947 @default.
- W2913950552 cites W2069642809 @default.
- W2913950552 cites W2071835038 @default.
- W2913950552 cites W2071965727 @default.
- W2913950552 cites W2073996535 @default.
- W2913950552 cites W2075680729 @default.
- W2913950552 cites W2075793841 @default.
- W2913950552 cites W2076140273 @default.
- W2913950552 cites W2080785707 @default.
- W2913950552 cites W2081188627 @default.
- W2913950552 cites W2086172007 @default.
- W2913950552 cites W2088883749 @default.
- W2913950552 cites W2094023488 @default.
- W2913950552 cites W2095767025 @default.
- W2913950552 cites W2102071852 @default.
- W2913950552 cites W2102354517 @default.
- W2913950552 cites W2108724455 @default.
- W2913950552 cites W2117065100 @default.
- W2913950552 cites W2118428015 @default.
- W2913950552 cites W2123319002 @default.
- W2913950552 cites W2124852816 @default.
- W2913950552 cites W2125461230 @default.
- W2913950552 cites W2127558621 @default.
- W2913950552 cites W2130356495 @default.
- W2913950552 cites W2131222480 @default.
- W2913950552 cites W2134979684 @default.
- W2913950552 cites W2145044522 @default.
- W2913950552 cites W2151317627 @default.
- W2913950552 cites W2158480093 @default.
- W2913950552 cites W2162140339 @default.
- W2913950552 cites W2164948885 @default.
- W2913950552 cites W2170141518 @default.
- W2913950552 cites W2170606300 @default.
- W2913950552 cites W2171127842 @default.
- W2913950552 cites W2178105210 @default.
- W2913950552 cites W2211963426 @default.
- W2913950552 cites W2270971263 @default.
- W2913950552 cites W2272315791 @default.
- W2913950552 cites W2344620176 @default.
- W2913950552 cites W2399787808 @default.
- W2913950552 cites W2401820359 @default.
- W2913950552 cites W2469476726 @default.
- W2913950552 cites W2475925552 @default.
- W2913950552 cites W2532914394 @default.
- W2913950552 cites W2559570574 @default.
- W2913950552 cites W2589420593 @default.
- W2913950552 cites W2728605505 @default.
- W2913950552 cites W2770385888 @default.
- W2913950552 cites W2785903681 @default.
- W2913950552 cites W2786178453 @default.
- W2913950552 cites W2791252329 @default.
- W2913950552 cites W2792638657 @default.
- W2913950552 cites W2824830902 @default.
- W2913950552 cites W4211123396 @default.
- W2913950552 cites W4244706225 @default.
- W2913950552 cites W911598418 @default.
- W2913950552 doi "https://doi.org/10.3233/jpd-181503" @default.
- W2913950552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30741689" @default.
- W2913950552 hasPublicationYear "2019" @default.
- W2913950552 type Work @default.
- W2913950552 sameAs 2913950552 @default.
- W2913950552 citedByCount "85" @default.